United States Antimony (UAMY) just announced a joint venture with Americas Gold and Silver to build what is described as the first commercial scale hydromet processing facility in North America for copper, silver, and antimony.

The joint venture headlines sit against a mixed share price backdrop, with a 1 day share price return of 3.11% and a year to date share price return of 28.50%. The 1 year total shareholder return of just over 3x and 3 year total shareholder return of more than 17x point to very strong longer term momentum, even after recent 7 day and 30 day pullbacks.

If this antimony story has piqued your interest in critical minerals, you might also want to scan our list of 30 best rare earth metal stocks as another way to broaden your search.

So with UAMY trading at a discount to both its analyst price target and some intrinsic value estimates after a huge 1 year and 3 year run, are you looking at a fresh opportunity, or a market that is already pricing in future growth?

Most Popular Narrative: 21.2% Undervalued

On the most followed narrative, United States Antimony’s fair value of $9.67 sits above the last close at $7.62, which puts a clear spotlight on the growth and margin assumptions that underpin that gap.

Ongoing property acquisitions and vertical integration (new mining leases in Alaska, Montana, and Ontario for antimony, gold, and tungsten) provide optionality and resource security; successful development and permitted production from these assets would further increase revenue potential, diversify supply risk, and bolster long-term earnings growth.

Curious what kind of revenue ramp and margin shift would need to sit behind that $9.67 number? The narrative leans on rapid top line expansion, a sharp swing into profitability, and a future earnings multiple that assumes investors stay willing to pay a premium for a critical minerals story rather than a mature commodity producer.

Result: Fair Value of $9.67 (UNDERVALUED)

However, there are real pressure points here, including permitting setbacks at Alaska and Ontario projects, as well as the risk that expected government offtake or funding support does not materialize.

Another Way To Look At The Valuation

The narrative and DCF work point to United States Antimony trading about 10.8% below an estimated fair value of $8.55, which reinforces the undervalued story. The key issue for investors is whether the cash flow assumptions behind that gap seem realistic, or overly optimistic, given the current risks.

Build Your Own United States Antimony Narrative

If the assumptions here do not quite fit how you see things, or you prefer to rely on your own work, you can build a tailored thesis in just a few minutes by starting with Do it your way.

A great starting point for your United States Antimony research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If you stop your research with a single stock, you risk missing other opportunities that might fit your style even better, so broaden your watchlist with curated ideas.

• Hunt for potential bargains that pair quality with attractive pricing by scanning our 53 high quality undervalued stocks for ideas that may warrant a closer look.
• Prioritise resilience by reviewing companies in the 85 resilient stocks with low risk scores that may better align with a capital preservation mindset.
• Spot earlier stage opportunities by checking the 28 elite penny stocks with strong financials where smaller names with different risk and reward profiles are collected in one place.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.